Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Insulin Resistance - Overview
Insulin Resistance - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Insulin Resistance - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Insulin Resistance - Companies Involved in Therapeutics Development
Amolyt Pharma
Exscien Corp
F. Hoffmann-La Roche Ltd
Hanmi Pharmaceuticals Co Ltd
Lixte Biotechnology Holdings Inc
Neurodon LLC
NorthSea Therapeutics BV
Pfizer Inc
Symmetry Therapeutics Inc
Insulin Resistance - Drug Profiles
AZP-3404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CDN-1163 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
englerin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Insulin Resistance - Dormant Projects
Insulin Resistance - Product Development Milestones
Featured News & Press Releases
Mar 21, 2019: Alize Pharma3 to present data from its AZP-3404program in syndromes of severe insulin resistance at ENDO2019
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Insulin Resistance, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development for Insulin Resistance, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Insulin Resistance - Pipeline by Amolyt Pharma, H2 2020
Insulin Resistance - Pipeline by Exscien Corp, H2 2020
Insulin Resistance - Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
Insulin Resistance - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2020
Insulin Resistance - Pipeline by Lixte Biotechnology Holdings Inc, H2 2020
Insulin Resistance - Pipeline by Neurodon LLC, H2 2020
Insulin Resistance - Pipeline by NorthSea Therapeutics BV, H2 2020
Insulin Resistance - Pipeline by Pfizer Inc, H2 2020
Insulin Resistance - Pipeline by Symmetry Therapeutics Inc, H2 2020
Insulin Resistance - Dormant Projects, H2 2020
Insulin Resistance - Dormant Projects, H2 2020 (Contd..1), H2 2020